The ceo is a scientist … investors here should focus on the science, data, patents and products. While Arthur Mikaelian may not be flashy like a television actor - he’s calm pragmatic and well versed in the $CIENCE. The money here will come from the patented polarization technology (read up on the Advil study - amazing the increased efficacy with smaller doses), money will come from escozine garnering recently being given the go ahead in the DR to be used for covid protocol, the money will come when escozine gets fda approval, … the money will come
In the mean time … waiting is boring
Listening to data can sound boring .. but when you listen to the data, and combine that with the potential uses (Advil was just a test - imagine chemo drugs more effective in less quantity? That equates to patients suffering less ) … the big picture is it’s all culminating together …. The Aelia products are great and will serve as a revenue stream - but part of the big picture is the Aelia products show proof of concept that the polarization technology not only works it works well!!!
Imunapen is huge as well.
I suggest to all give the products a try … have patience for the fda and ticker change … but ultimately, decades of research is on the precipice of being $$$
Qnta MedolifeRx Aelia escozine
